Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study.

J Clin Med · 2025 · PMC12565265 · PMID 41156158

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although PFS was similar between groups, the TMZ+IRI regimen demonstrated a favorable trend in disease control, with a comparable 6-month PFS rate.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.